Navigation Links
Omeros Reports Additional Positive Results from OMS824 Program
Date:9/12/2013

r/>Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates, OMS302 for lens replacement surgery and OMS103HP for arthroscopy, are derived from its proprietary PharmacoSurgery® platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has six clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the pharmaceutical industry. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, coagulopathies and central nervous system disorders.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the "safe harbor" created by those sections for such statements. These statements include, but are not limited to, Omeros' expectations regarding the potential competitive advantages of OMS824, including its therapeutic benefits; that it will advance OMS824 into Phase 2 clinical programs for Huntington's disease and schizophrenia before year end; regarding the potential qualities of OMS824; regarding demonstration of target engagement in the PET trial; and that it may have capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the pharmaceutical industry. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could di
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency
2. Omeros to Present at the Stifel Healthcare Conference 2013
3. Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer
4. Omeros Corporation Reports Second Quarter 2013 Financial Results
5. Omeros to Present at the Wedbush 2013 Life Sciences Management Access Conference
6. Omeros Submits New Drug Application to U.S. FDA for OMS302
7. Omeros Reports Positive Results from OMS824 Positron Emission Tomography Clinical Trial
8. Omeros Files Clinical Trial Application for Lead Antibody in MASP-2 Program
9. Omeros Corporation Reports First Quarter 2013 Financial Results
10. Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
11. Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014  PTC Therapeutics, Inc. (NASDAQ: ... host a webcast conference call to report its second ... the company,s business and outlook on Thursday, August 7, ... the market. The call can be ... (international) five minutes prior to the start of the ...
(Date:7/24/2014)... 24, 2014  Abaxis, Inc. (NasdaqGS: ABAX ... systems, today reported financial results for the first fiscal ... overview: , Revenues of $47.5 million, up 10% ... of $0.21, up 50% over last year,s comparable quarter. ... of $7.2 million, up 20% over last year,s comparable ...
(Date:7/24/2014)... -- IGI Laboratories, Inc. (NYSE MKT: IG), a ... company, today announced it has accepted  Damian Finio,s ... has accepted a senior level finance position at a ... of his new position, Mr. Finio will be unable ... Laboratories, Inc.  The effective date of his resignation will ...
Breaking Medicine Technology:Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2
... (NASDAQ: SIAL ) today announced that its ... ), is introducing a novel CHOZN® GS-/- Zinc Finger ... for use in the production of biopharmaceuticals, the new ... glutamine synthetase (GS) knockout CHO cell line proven to ...
... LAS VEGAS, Oct. 26, 2011 Clinical Research Management, ... basic and applied research, clinical trials, and regulatory support, ... Boyer, Ph.D., will co-present a panel titled Battle ... the MAGI West Clinical Research Conference, October 23-26, 2011 ...
Cached Medicine Technology:SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 2SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 3SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 4ClinicalRM to Co-Present Regulatory Compliance Panel at MAGI 2
(Date:7/25/2014)... July 25, 2014 Ticket Down ... Inter Milan tickets in Berkeley at California Memorial Stadium. ... new fans of football, the organizers of the 2014 Guinness ... club teams to North America. With teams representing La Liga, ... will bring some of the best football players from around ...
(Date:7/25/2014)... 25, 2014 On July 22, ... Media client and the nation’s number one provider ... handbooks, announced their partnership with TransAct Merchant Solutions’ ... registered ISO/MSP of Chase Paymentech Solutions, LLC, which ... industry. Companies that are members of TransAct’s National ...
(Date:7/25/2014)... Hastings and Hastings, a personal injury ... to personal injury claims, announces free initial consultations. Hastings ... services for those that have been injured as a ... Free initial consultation services gives clients’ greater flexibility in ... personal injury claim . It also offers clients the ...
(Date:7/25/2014)... News) -- Shift workers, especially men, may be at higher ... such schedules, a new study suggests. Also at special ... schedule, with shifts moving around at various times of the ... one expert, Dr. Alan Manevitz, a clinical psychiatrist at Lenox ... known that working shifts disrupts many key body chemicals, creating ...
(Date:7/25/2014)... protect vulnerable neurons and reduce motor deficits in ... Emory University School of Medicine have shown. , ... of Parkinson,s Disease . , The findings demonstrate ... brain at sufficient levels and have beneficial effects ... shot. Previous studies of XPro1595 in animals tested ...
Breaking Medicine News(10 mins):Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3Health News:Study Links Shift Work to Risk for Type 2 Diabetes 2Health News:Study Links Shift Work to Risk for Type 2 Diabetes 3Health News:Anti-inflammatory drug can prevent neuron loss in Parkinson's model 2
... Jan. 6 (HealthDay News) -- Weight loss surgery isn,t likely ... sugar control, a new study suggests. Obesity is a ... that gastric bypass surgery can cure diabetes in up to ... stomach to form a smaller pouch and connecting it to ...
... (HealthDay News) -- The blood pressure medicine losartan [Cozaar] ... to cigarette smoke for two months, researchers say. ... thickening, inflammation and lung overexpansion in the animals, according ... led to a clinical trial of losartan in people ...
... of New York (CCNY) whose research unites the divergent ... be honored this month for his pioneering work in ... and photonics. SPIE will present Dr. Robert Alfano, ... with the first annual Britton Chance Biomedical Optics Award ...
... Fla. (Jan. 6, 2012) A malignancy-risk gene signature ... predictive and prognostic value for patients with early stage ... researchers at Moffitt Cancer Center in Tampa, Fla., who ... the Journal of the National Cancer Institute . ...
... Steven Reinberg HealthDay Reporter , THURSDAY, Jan. ... a U.S. advisory panel,s recommendation to lower the threshold ... metal once common in gasoline and house paint, can ... Advisory Committee on Childhood Lead Poisoning Prevention voted to ...
... By Alan Mozes HealthDay Reporter , THURSDAY, ... seniors may double their risk of developing a particularly ... disease, a large new European study suggests. The ... macular degeneration (AMD), a significant cause of blindness in ...
Cached Medicine News:Health News:Weight Loss Surgery May Help Diabetes 2Health News:Mice Exposed to Smoke Helped by Blood Pressure Drug: Study 2Health News:CCNY's Robert Alfano wins first biomedical optics award 2Health News:CCNY's Robert Alfano wins first biomedical optics award 3Health News:Researchers find malignancy-risk gene signature for early-stage non-small cell lung cancer 2Health News:Experts Endorse Lower Lead-Poisoning Threshold 2Health News:Experts Endorse Lower Lead-Poisoning Threshold 3Health News:Could Daily Aspirin Harm Seniors' Eyes? 2Health News:Could Daily Aspirin Harm Seniors' Eyes? 3
For lipoplasty of trochanteric area, abdomen, thighs, hips, buttocks and flanks...
CDIs original garments with our exclusive Wonderfabric™....
Black Spandex Above the Knee Compression Girdles with Contact Closure with Zipper...
Black Spandex Above the Knee Compression Girdles with Hook & Eye with Zipper...
Medicine Products: